SGK Updates List of Foreign Medicines – Effective Jan 17, 2026
SGK Updates List of Foreign Medicines – New Euro-Based Prices Published in Resmi Gazete
The Social Security Institution (SGK) of Turkey has enacted a significant update to the reimbursement list for foreign-origin medicines. The new euro-based pricing, determined by the Pricing Commission, was officially published in the Resmi Gazete (Official Gazette) and took effect immediately upon notification. The updated prices are officially applicable as of January 17, 2026.
Medicines Included in the Updated List
The revised list encompasses a range of critical drugs used in the treatment of various chronic and complex conditions. Key therapeutic areas covered include:
- Cardiac arrhythmias (e.g., Flecainide acetate)
- Respiratory conditions (e.g., Glycopyrrolate)
- Rheumatological and autoimmune diseases (e.g., Hydroxychloroquine sulfate)
- Chronic neurological and muscular disorders (e.g., Epilepsy medications, Melp Spal-P)
- Gastrointestinal and metabolic conditions (e.g., Sucraid)
- Immunotherapy (e.g., Immukin)
Key Price Updates (Euro-Based)
The following are selected examples of the newly published euro prices for specific medications and strengths:
- Flecainide acetate 100 mg (cardiac arrhythmia) — Approximately €11.30
- Glycopyrrolate 1 mg (respiratory) — €59.00
- Hydroxychloroquine sulfate 200 mg (rheumatology/immunity) — €17.55
- Jamp Tretinoin 10 mg (chronic skin conditions) — €185.00
- Sucraid oral solution (GIT enzyme deficiency) — €1,715.00
- Immukin injectable solution (immunotherapy) — €838.00
- Melp Spal-P 50 mg (muscular and nervous system) — €29.50
- Rufinamide-based medications (epilepsy) — Ranging from €52 to €88
SGK Statement: "Medications that are not produced domestically in Turkey or are facing supply shortages will continue to be reimbursed within the scope of health insurance, in accordance with the approved euro-based price list."
What This Means for Patients
This regulatory update provides clarity and continuity for patients relying on essential foreign medicines. The SGK reaffirms that these critical treatments, particularly those without a local equivalent or available supply, will remain accessible under the national health insurance (reimbursement) system at the newly determined prices.
Important Note: Patients are advised to consult with their physicians and pharmacists regarding the specific coverage and co-payment details for their prescribed medications under the updated list.
